Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema type I and II in patients who require rapid symptom control.

GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema. - Hereditary angioedema type I: rapid reduction of acute swelling episodes. - Hereditary angioedema type II: rapid reduction of acute swelling episodes. - Hereditary angioedema (any type): mitigation of attack severity and duration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin discoloration. - Swelling at injection site: transient increase in tissue volume. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate head discomfort. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling. - Injection‑site infection: signs of local infection. - Thrombosis: rare clot formation at or near injection site.

Before using Icatibant, consider the following safety measures. - Renal impairment: monitor renal function and adjust clinical observation. - Hepatic impairment: use with caution and observe liver enzymes. - Pregnancy: safety not established; weigh benefits against potential risks. - Concomitant ACE inhibitors: monitor for enhanced bradykinin effects. - History of hypersensitivity: avoid if prior allergic reaction to the drug. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medicines; review the following. Major Interactions (Avoid): - ACE inhibitors: additive increase in bradykinin levels may worsen edema. - Angiotensin receptor blockers: similar risk of heightened bradykinin activity. - Other bradykinin B2 antagonists: potential for overlapping pharmacologic effect. Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolyte balance. - NSAIDs: observe for increased risk of swelling or renal effects. - Corticosteroids: watch for altered immune response at injection site.